|
Jul 1
|
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
|
|
Jun 18
|
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
|
|
Jun 2
|
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
|
|
Jan 2
|
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
|
|
Jun 25
|
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
|
|
Jun 20
|
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
|
|
Sep 11
|
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
|
|
Sep 5
|
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
|